Clinical Trial Update: An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

View source ↗

Summary

An open-label, multi-center expansion of Pasireotide LAR treatment for acromegaly is discussed, with the product listed as approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Status: APPROVED_FOR_MARKETING